In the current study, Bartelt and colleagues compared outcomes among 7,773 patients who were prescribed phentermine approved by the FDA for weight management in 1959 after discontinuing a GLP-1 receptor agonist with 34,668 patients who were not prescribed phentermine after GLP-1 discontinuation
Commence Your Journey with Klinic Today Although you might have initially gravitated toward Ozempic in Hilton Head Island, consider Wegovy, oral Wegovy, Zepbound, or Foundayo for deliberate and sustained weight management through Klinic's comprehensive care
However, they determined that the strength of the evidence for these associations was limited, and some of the studies did not adequately correct for potential confounders such as the severity of depression, hormone levels, and lifestyle factors, among other variables
We are not aware of any trial exploring the effect of empagliflozin on body weight in people without T2D at the time of writing
If you found Understanding the GLP-1 Receptor Agonist: Effects, Risks, and Diabetes Medicine helpful, we encourage you to continue exploring our research-based articles to make informed decisions about your health